Galectin-1–FIP200 Axis Impairs Autophagy in Hepatic Steatosis

Study Background and Research Question

Non-alcoholic fatty liver disease (NAFLD) has emerged as the most common chronic liver disorder globally, encompassing a spectrum from simple steatosis to non-alcoholic steatohepatitis (NASH), fibrosis, and hepatocellular carcinoma. Despite its prevalence, the molecular mechanisms connecting metabolic stress, autophagy dysregulation, and disease progression remain incompletely understood. Central to NAFLD is hepatic insulin resistance, but the upstream mediators that disturb cellular quality control pathways, such as autophagy, are not fully characterized. Recent attention has turned to galectins, particularly galectin-1 (Gal-1), a β-galactoside-binding lectin implicated in metabolic and inflammatory disorders. The current study (International Immunopharmacology 185 (2026) 116984) seeks to elucidate whether Gal-1 directly impairs hepatic autophagy and thereby exacerbates steatosis and insulin resistance.

Key Innovation from the Reference Study

The principal innovation of this work is the identification of a direct inhibitory mechanism by which Gal-1 suppresses hepatic autophagy through its interaction with the core autophagy scaffold protein FIP200. By mapping the binding interface and demonstrating that Gal-1 overexpression alone is sufficient to induce NAFLD-like phenotypes, the authors establish the Gal-1–FIP200 axis as a central regulatory node in metabolic liver disease. This mechanism represents a previously unrecognized link between lectin signaling and autophagic flux, with direct implications for disease pathogenesis and therapeutic targeting.

Methods and Experimental Design Insights

The investigators adopted a multifaceted approach combining in vivo, in vitro, and proteomics methodologies to dissect the Gal-1–autophagy pathway:

• Transgenic Mouse Models: Mice with hepatic Gal-1 overexpression were generated to assess the impact on liver lipid accumulation, insulin sensitivity, and autophagic markers in the absence of dietary or pharmacological stressors.
• Proteomic Profiling: Global proteomics and targeted immunoblotting were used to evaluate changes in autophagy-related proteins, including p62 and LC3-II, as readouts of autophagic flux.
• Protein Interaction Studies: Co-immunoprecipitation, structural mapping, and binding affinity assays defined the interaction interface between Gal-1 and FIP200, pinpointing key residues (Gal-1 TYR120/PHE134 and the FIP200 claw domain) responsible for functional effects.
• Mutational Analysis: Site-directed mutagenesis disrupted the Gal-1–FIP200 interaction, enabling functional validation of the autophagy impairment mechanism.
• Functional Assays: Insulin signaling, lipid uptake, and cell viability assays in hepatocyte cultures complemented the in vivo findings.

Core Findings and Why They Matter

The study demonstrates several critical findings (reference):

• Gal-1 overexpression in mouse liver is sufficient to induce hepatic steatosis, dyslipidemia, and insulin resistance, recapitulating key NAFLD features even without high-fat diet challenge.
• Proteomic and immunoblot evidence shows a marked blockade of autophagic flux in Gal-1–overexpressing livers, with p62 accumulation and impaired LC3-II conversion.
• Gal-1 binds directly to FIP200, a central component of the ULK1 autophagy initiation complex, disrupting complex assembly and reducing FIP200 expression at both transcriptional and post-translational levels.
• Structural and binding studies identify a bipartite interface with a Kd of 113.1 μM, and disruption of this interaction by point mutation abolishes Gal-1’s ability to suppress autophagy and induce insulin resistance in cell models.
• Collectively, these results establish the Gal-1–FIP200 axis as a driver of autophagy impairment and metabolic dysfunction in NAFLD.

This work advances mechanistic understanding of how metabolic and inflammatory cues converge on autophagy regulation and highlights Gal-1 as a potential therapeutic target for liver metabolic disorders.

Comparison with Existing Internal Articles

The mechanistic insights from this study align with recent internal reviews emphasizing the role of autophagy impairment in NAFLD progression. The article "Galectin-1–FIP200 Disruption Drives Hepatic Steatosis via Autophagy Impairment" independently underscores the significance of the Gal-1–FIP200 interaction in modulating hepatic lipid metabolism and disease phenotype. Meanwhile, translational perspectives such as "ASK1 Inhibition with Selonsertib: New Frontiers in NAFLD Research" place these findings in the broader context of stress signaling and fibrosis, discussing the intersection of autophagy, oxidative stress, and inflammation in metabolic liver disease. These resources together provide a conceptual framework for researchers interested in dissecting the autophagy-fibrosis axis and evaluating ASK1 pathway inhibitors in relevant disease models.

Limitations and Transferability

While the study presents compelling evidence for the Gal-1–FIP200 axis in murine and cellular models, several limitations should be considered:

• Species Specificity: Most experiments were conducted in mice or murine hepatocyte cultures; direct relevance to human NAFLD and liver disease progression requires further validation.
• Context of Metabolic Stress: The pro-steatotic effects of Gal-1 were observed even without dietary challenge, but the interplay with high-fat or high-sugar diets and other environmental factors remains unexplored.
• Therapeutic Modulation: Although the Gal-1–FIP200 interface represents a promising target, no direct inhibitors are currently validated, and potential off-target effects of modulating Gal-1 signaling need investigation.
• Autophagic Flux Measurement: The use of p62 and LC3-II as autophagy markers is standard, but flux assessment can be confounded by altered synthesis or degradation rates; complementary methods may improve interpretability.

Overall, the findings are robust in preclinical models but should be interpreted as foundational for further translational and interventional studies.

Protocol Parameters

• Gal-1 Overexpression: Employ liver-specific Gal-1 transgenic models or adenoviral overexpression systems; validate with immunoblotting and qRT-PCR.
• Autophagy Assessment: Quantify LC3-II and p62 levels via immunoblotting before and after lysosomal inhibition (e.g., bafilomycin A1 treatment) to distinguish flux blockade from increased autophagosome synthesis.
• Protein Interaction Disruption: Use site-directed mutagenesis to target Gal-1 (TYR120/PHE134) or FIP200 claw domain residues for mechanistic studies.
• Metabolic Phenotyping: Assess hepatic triglyceride content, plasma lipid profile, and insulin sensitivity (e.g., glucose and insulin tolerance tests) for functional readouts.

Research Support Resources

For researchers aiming to dissect oxidative stress, inflammation, and fibrosis pathways in metabolic liver disease, selective pharmacological tools are essential. Selonsertib (GS-4997) (SKU B7812) is a highly selective ASK1 inhibitor that enables precise investigation of oxidative stress and inflammation signaling in both hepatic and renal models. Its distinct ATP-competitive inhibition profile and documented utility in fibrosis and diabetic kidney disease workflows make it suitable for studies targeting the autophagy-fibrosis axis, as highlighted in recent translational articles. Selonsertib is available from APExBIO with high purity and solubility for diverse experimental needs; researchers are encouraged to consult the product documentation for optimal use in workflow design.